An Australian stem cell and regenerative medicine company
About Us
About Us
What We Do
Board Of Directors
Management
Scientific Advisors
Corporate Governance
Company History
Clinical Development
Graft-versus-host-disease
Osteoarthritis
Acute respiratory distress syndrome
Diabetic Wounds
Renal transplantation
Pre-clinical Development
Asthma
Heart Attack
Coronary Artery Disease
Brain Cancer
Sepsis
Critical Limb Ischemia
Idiopathic pulmonary fibrosis
Science & Technology
Cymerus Technology
About MSCs
About iPSCs
Science Publications
Investors
Stock Information
ASX Announcements
Financial Reports
Presentations
Corporate Governance
Analyst Research
Investor FAQs
Right to Receive Documents
Newsroom
FAQ
Company FAQs
Investor FAQs
Contact Us
Science Publications
Kelly K et al. Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease. Nat Med. 2024
Hodgson-Garms M et al. A comparative analysis of the MSC transcriptome: Human iPSC-derived MSCs and their tissue-derived counterparts. ASSCR 2022 Poster.
Romanazzo S et al. Biomaterials directed activation of a cryostable therapeutic secretome in iPSC derived MSCs. Tissue Eng Regen Med. 2022;16(11):1008-1018.
Liu X et al. Efficacy and cost-effectiveness of stem cell injections for symptomatic relief and structural improvement in people with tibiofemoral knee osteoarthritis. BMJ Open. 2021;11(11):e056382
Kelly K, Rasko JEJ. Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease. Front Immunol. 2021;12:761616.
Thavapalachandran S et al. Pluripotent stem cell-derived mesenchymal stromal cells improve cardiac function and vascularity after myocardial infarction. Cytotherapy. 2021;23(12):1074-1084.
Bloor AJC et al. Production, safety and efficacy of iPSC-derived MSCs in acute steroid-resistant graft versus host disease: a phase I study. Nat Med. 2020;26(11):1720-1725.
Millar JE et al. Combined MSC and Therapy and ECMO in Acute Respiratory Distress Syndrome. A Randomized Controlled Trial in Sheep. Am J Respir Crit Care Med. 2020;202(3):383-392.
Rasko JEJ et al. Results of the First Completed Clinical Trial of an iPSC-Derived Product: CYP-001 in Steroid-Resistant Acute GvHD. TCT 2019 Poster.
Khan MA et al. iPSC-derived MSC therapy induces immune tolerance and supports long-term graft survival in mouse orthotopic tracheal transplants. Stem Cell Res Ther. 2019;23;10(1):290.
Royce SG et al. iPSC- and MCA-derived MSCs provide greater protection against experimental chronic allergic airways disease compared with a clinically used corticosteroid. FASEB J. 2019;33:6402-11.
Kelly K. Can iPSCs Address the Challenge of Maintaining Consistent Quality in Starting Materials Used in the Manufacture of Cell-Based Therapies? Cell & Gene Therapy Insights. 2019; 5(2), 227-232.
Ozay EI et al. Cymerus™ iPSC-MSCs significantly prolong survival in a pre-clinical, humanized mouse model of Graft-vs-host disease. Stem Cell Res. 2019;35:101401.
Kelly K. Next-generation cell-based therapies: the potential of IPSCs. Australasian Biotechnology. 2017;27(3):14-16.
Royce SG et al. Intranasal administration of MCA-derived MSCs abrogates airway fibrosis and airway hyperresponsiveness associated with chronic allergic airways disease. FASEB J. 2017;31(9):4168-4178.
Koch JM et al. MCA-derived MSCs inhibit cell damage, tissue damage and improve peripheral blood flow following hindlimb ischemic injury in mice. Cytotherapy 2016;18:219–228.
Kelly K. Limitless starting materials for large-scale manufacture of MSCs – what does the future hold? Pharm Bioprocess. 2015;3:281-283.
Vodyanik MA et al. A Mesoderm-Derived Precursor for Mesenchymal Stem and Endothelial Cells. Cell Stem Cell 2010;7(6):718-29.